• Led R&D processed team for over 1200 patient tumor samples at Xsphera Biosciences • Established a growing team (over 20 people) of research and development • Delivered preclinical data and clinical biomarker endpoints for more than 1200 samples for therapeutics in support of clinical trials • Establish revenue-generating collaborations with big pharma industry partners ($3.5M/Y)• Designed a company-NCI sponsored clinical collaboration with Moffitt Hospital in immuno-oncology projects (PI of the NCI SBIR grant: $350,000)• Fostered collaborations with key opinion leaders and external partners to stay at the forefront of developments in translational sciences• Provided the visionary leadership for a $50 Million technology company offering a functional, precision immune-oncology solutions and companion diagnostics for patients, providers, and pharmaceutical companies• Monitored oncology immunotherapeutic landscape and served as subject matter expert for tumor microenvironment

• Built and led productive research unit that delivered a continuous stream of therapeutics to the R&D• provided strategic direction for Toxicology/Pathology, Biomarkers, teams to ensure robust support for clinical development programs.• Profiled ex vivo model of PD-1 Blockade Using Patient-derived Organotypic Tumors Spheroids • Identified a short-term culture of organotypic tumor spheroids derived from patient xenografts in a novel 3D microfluidic chip predicts in vivo response of targeted therapies

1) Characterize, in a 3D-device, the inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit in human lung cancer cells (collaboration with Dr. David Barbie).2) Measure the response to cancer therapeutic agents in a 3D controlled microenvironment. 3) Measure signaling pathways during EMT (epithelial-mesenchymal transition) in 3D microfluidic device. 4) Validate the use of novel smart chitosan nanoparticles for antisense delivery using a microfluidics platform (collaboration with Dr. Michael Hamblin, MGH).

1) Developed and validated 3D-microenvironment devices for assaying EMT-blocking agents in human lung cancer cells (collaboration with Prof. Jean-Paul Thiery).2) Designed and implemented 3D-microenvironments devices for co-culture of human cells for angiogenesis research projects.